Kymera Therapeutics Stock (NASDAQ:KYMR)
Previous Close
$89.89
52W Range
$19.45 - $103.00
50D Avg
$63.20
200D Avg
$44.78
Market Cap
$6.32B
Avg Vol (3M)
$951.53K
Beta
2.29
Div Yield
-
KYMR Company Profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| VKTX | Viking Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| AKRO | Akero Therapeutics, Inc. |
| IMVT | Immunovant, Inc. |